Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine if intravitreal tissue plasminogen activator (tPA), gas (C3F8) and ranibizumab promote the resolution of submacular haemorrhage (SMH) due to neovascular (wet) age-related macular degeneration, and improve the visual outcome. The primary outcome measure will be the change in mean ETDRS visual acuity at 3 months following treatment. [Lay notes: ETDRS visual acuity is vision assessed using a specialized eye chart.Please see the lay summary for the other clinical terms in this section]
Critère d'inclusion
- Sub-macular haemorrhage secondary to wet macular degeneration